Advertisement

Clinical Experience with UFT in Japan

  • Minoru Kurihara
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 339)

Abstract

UFT is an anticancer drug combining Tegafur and uracil in a molar ratio of 1 to 4. Tegafur is absorbed well not only by oral route but also by intrarectal administration, then the Tegafur is gradually converted to 5-FU mainly in the liver microsomes 1 in vivo, and certain level of 5-FU in blood is maintained for a longer period. Furthermore, the incidence of side effects with Tegafur is very low, therefore it can be administered for long period, and from such reasons it has been widely used in clinical practice.

Keywords

Gastric Cancer Median Survival Period Generalize Wilcoxon Test Intrarectal Administration Lesion Subtype 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    H. Toide, H. Akiyoshi, Y. Minato, H. Okuda and S. Fujii, Comparative Studies on the Metabolism of 2-(Tetrahydrofuryl)-5-fluorouracil and 5-Fluorouracil, Gann. 68: 553–560 (1977).PubMedGoogle Scholar
  2. 2.
    S. Fujii, K. Ikenaka, M. Fukushima and T. Shirasaka, Effect of Uracil and its Derivatives on Antitumor Activity of 5-Fluorouracil and 1-(2-Tetrahydro-furyD-5-fluorouracil, Gann. 69: 763–772 (1978).PubMedGoogle Scholar
  3. 3.
    S. Fujii, S. Kitano, K. Ikenaka and T. Shirasaka, Effect of Coadministration of Clinical Doses of 1-(2-Tetrahydrofuryl)-5-fluorouracil and Level of 5-Fluorouracil in Rodents, Gann. 70: 209–214 (1979).PubMedGoogle Scholar
  4. 4.
    Y. Fukui, N. Imabayashi, M. Nishi, K. Majima, M. Yamamura, K. Hioki and M. Yamamoto, Clinical Study on the Enhancement of Drug Delivery into Tumor Tissue by Using UFT, Jpn. J. Cancer Chemother. 7 (12): 2124–2129 (1980).Google Scholar
  5. 5.
    K. Kimura, S. Suga, T. Shimaji, M. Kitamura, K. Kubo, Y. Suzuoki and K. Isobe, Clinical Basis of Chemotherapy for Gastric Cancer with Uracil and 1-(2-Tetrahydrofuryl)-5-flurouracil, Gastroenterologia Japonica. 15 (4): 324–329 (1980).PubMedGoogle Scholar
  6. 6.
    M. Maeta, A. Izumi, R. Hamazoe, Y. Osaki, N. Shimazu and S. Koga, Intratumorous 5-FU Consentration after Coadministration of FT-207 with Uracil, Igaku No Ayumi. 116: 97–100 (1981).Google Scholar
  7. 7.
    K. Ota, T. Taguchi and K. Kimura, Report on Nationwide Pooled Data and Cohort Investigation in UFT Phase II Study, Cancer Chemother. Pharmacol. 22: 333–338 (1988).PubMedCrossRefGoogle Scholar
  8. 8.
    M. Kurihara, T. Akiya, K. Futatsuki et al, Evaluation of Chemotherapeutic Effect on Advanced Gastric Cancer Cases with Primary Focus by the Criteria of Chemotherapeutic Effects on Gastric Cancer, Oncologia. 21 (2): 93–97 (1988).Google Scholar
  9. 9.
    Y. Takahashi, R. Kikuchi, M. Ueno and M. Mai, Effect of Combination of UFT and MMC (UFT-M Thrapy) on Human Colonic Cancer Xenotransplanted in Nude Mice, Jpn. J. Cancer Chemother. 14 (5): 1345–1347 (1987).Google Scholar
  10. 10.
    P. Preusser, H. Wilke, W. Achterrath et al, Advanced Gastric Carcinoma: A Phase II Study with Etoposide(E), Adriamycin(A) and Spilit Course Cisplatin(P)=EAP, Proc. of Amer. Soc. Clin. Oncol. 6: 292 (1987).Google Scholar
  11. 11.
    M. Hayakawa, K. Morise, T. Sakai et al, Combination Chemotherapy with UFT Etoposide. CDDP. Adriamycin(FEPA) in Advanced Gastric Cancer, Jpn. J. Cancer Chemother. 16 (10): 3393–3398 (1989).Google Scholar

Copyright information

© Springer Science+Business Media New York 1993

Authors and Affiliations

  • Minoru Kurihara
    • 1
  1. 1.Department of Internal MedicineToyosu Hospital, Showa UniversityTokyoJapan

Personalised recommendations